Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy
Estimating the term…
Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
A mouse whose germline genome comprises an endogenous immunoglobulin (Ig) heavy chain locus modified to comprise a human genomic germline kappa (κ) sequence comprising
-14. (canceled)
A mouse that expresses from its germline an immunoglobulin comprising a first polypeptide comprising a first human light chain variable region sequence fused with an immunoglobulin heavy chain constant region, and a second polypeptide comprising a second human light chain variable region fused with an immunoglobulin light chain constant region.
-21. (canceled)
An antigen-binding protein comprising a first dimer that comprises:
Dependencies are inferred from the claim text.